REOLYSIN® + Gemcitabine + Cisplatin
Phase 1Withdrawn 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Muscle-invasive Transitional Cell Carcinoma of the Bladder
Conditions
Muscle-invasive Transitional Cell Carcinoma of the Bladder
Trial Timeline
Feb 28, 2017 → Feb 28, 2018
NCT ID
NCT02723838About REOLYSIN® + Gemcitabine + Cisplatin
REOLYSIN® + Gemcitabine + Cisplatin is a phase 1 stage product being developed by Oncolytics Biotech for Muscle-invasive Transitional Cell Carcinoma of the Bladder. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02723838. Target conditions include Muscle-invasive Transitional Cell Carcinoma of the Bladder.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02723838 | Phase 1 | Withdrawn |
Competing Products
12 competing products in Muscle-invasive Transitional Cell Carcinoma of the Bladder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enfortumab Vedotin + Pembrolizumab | Astellas Pharma | Phase 2 | 52 |
| Pembrolizumab + Enfortumab Vedotin | Astellas Pharma | Phase 3 | 77 |
| Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG) | AstraZeneca | Phase 3 | 77 |
| Durvalumab (Imfinzi) + Tremelimumab | AstraZeneca | Phase 2 | 52 |
| Pembrolizumab + Gemcitabine | Merck | Phase 2 | 52 |
| Chemotherapy + Immunotherapy Induction + Immunotherapy Maintenance | Merck | Phase 2 | 52 |
| Autogene Cevumeran + Nivolumab + Saline | Roche | Phase 2 | 52 |
| Atezolizumab | Roche | Phase 3 | 77 |
| Nivolumab + Nab-paclitaxel + Nivolumab | Bristol Myers Squibb | Phase 2 | 51 |
| Cretostimogene Grenadenorepvec | CG Oncology | Phase 2 | 49 |
| CG0070 + Nivolumab | CG Oncology | Phase 1 | 30 |
| AU-011 | Aura Biosciences | Phase 1 | 25 |